Revenue growth of 9.1% to USD 52.5 million - above-market
growth in core monitoring services resulting in market share gains
- substantial increase in profitability as efficiency measures bear
fruit - EBITDA margin of 13.8% achieved - net profit of USD 1.9
million vs. net loss of USD 4.7 million in H1 2014 - full-year
guidance reiterated
LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and
provider of medical solutions and remote diagnostic monitoring
services in the digital health market, is pleased to report on good
progress during the first half of 2015. In total, revenues during
the first six months amounted to USD 52.5 million, an increase of
9.1% compared to the prior year period. Monitoring services (99.7%
of revenues) grew by 12.1%, clearly outperforming the market
average and thus resulting in market share gains. During the first
half year, our US-based subsidiary LifeWatch Services Inc. signed
40 new or amended contracts, underpinning our brand and sales force
successes. Device sales declined to USD 0.2 million due to delivery
delays into the second half of 2015. The gross profit margin
amounted to 52.8% versus 52.1% a year earlier. We expect the gross
margin to continue to expand mid-term as on-going cost and
efficiency measures, product mix improvements and new project
launches take effect.
Substantial improvement in operating profitability
Our operating profitability improved substantially thanks to the
positive impact of the restructuring and productivity measures that
we implemented over the past year. As such, EBITDA during the first
half year reached USD 7.2 million (H1 2014 LBITDA of USD -1.5
million), equivalent to an EBITDA margin of 13.8%, and EBIT
amounted to USD 3.8 million (EBIT margin of 7.3%), marking the
highest levels since the first half of 2009. Significant progress
was achieved in Sales & Marketing thanks to sales force
optimization and territory realignment, resulting in an 800 bps
reduction to 18% of revenues (H1 2014: 26%). Likewise, the
reorganization of the R&D activities during the second half of
2014 as well as the capitalization of some development costs led to
a 300 bps reduction in R&D to 3.8% of revenues. Without
capitalization, R&D expenses would represent 5.7% of revenues
(H1 2014: 8%). Thanks to these substantial cost savings, together
with slightly lower General & Administration costs, the absence
of restructuring charges and despite a higher tax charge, LifeWatch
was able to achieve a positive net income of USD 1.94 million
during the first half of 2015, compared to a net loss of USD 4.72
million during the prior period. As a result of this good operating
performance, the company generated a cash flow from operations of
USD 4.2 million during the first six months of 2015, against a cash
drain of USD 2.8 million during H1 2014. The equity ratio stood at
54.3% as of June 30, 2015 (53.4% as of December 31, 2014).
On-going development and market activities
As previously announced, development activities are continuing
on both our cardiac and vital signs monitoring patches. The pilot
trials for the vital signs monitoring system are on-going with two
new clinics being added in September, one in the United States and
one in Switzerland. The FDA's enforcement of its new guidances on
medical devices "Design Considerations for Devices Indicated for
Home Use" and "Mobile Medical Applications" has resulted in
unexpected minor delays in obtaining the requisite FDA clearances
for LifeWatch's cutting-edge technologies. Clearance for the vital
signs monitoring system is however still expected later this year,
allowing for a limited market release during the fourth quarter.
The cardiac monitoring patch is currently being tested in a
hospital environment. Here again, the new FDA guidance is somewhat
delaying regulatory clearance, although we still anticipate a full
market launch later this year.
Positive news was received in July regarding an 8% increase in
the reimbursement rate from Medicare for our Telemetry offering
(ACT) as of 2016. This should lead to improved revenues and profits
of around USD 3.5 million in 2016. This change will further enhance
our expected revenue growth for 2016 and beyond.
Furthermore, we are on track to launch our cardiac monitoring
business in the Turkish market in the first half of 2016 and are
currently in the process of establishing the necessary organization
and infrastructure to meet this goal. This is a first step in the
global expansion of our remote cardiac monitoring services.
Although these development activities, as well as other
opportunities currently under review, involve significant costs in
the short-term, we believe they are necessary to enhance our future
growth and thereby remain a leader in this rapidly growing digital
health market.
Outlook
LifeWatch stands by its full-year 2015 guidance. The company is
continuing its efforts to update and grow its core business while
at the same time launching new products and entering new markets.
Dr. Stephan Rietiker commented: "Our market growth and efficiency
programs are progressing well and I am particularly excited about
the prospects for our new products and of our new markets. We
firmly believe that we are setting the stage for continued above
average growth and increased profitability in the years to
come."
Key figures (unaudited, USD millions):
H1 2015
H1 2014
Revenues 52.51 48.12 Gross profit 27.75 25.09 As % of revenues
52.8% 52.1% EBITDA / (LBITDA) 7.23 (1.52) As % of revenues 13.8% NA
EBIT / (LBIT) 3.81 (4.13) As % of revenues 7.3% NA Net income
(loss) 1.94 (4.72) As % of revenues 3.7% NA Earnings (loss) per
share 0.14 (0.36) Total fixed assets, net 16.22 13.02 Total assets
71.94 68.54 Total equity 39.04 34.82 As % of total assets 54.3% 51%
Net cash flow 0.02 (3.92) Employees 612 561
Detailed reporting
The report on the first half 2015 can be found on our website
using the following link:
http://irlifewatch.com/websites/lifewatch_ir/English/4020/interim-reports.
html
The presentation on the first half 2015 is available under this
link:
http://irlifewatch.com/websites/lifewatch_ir/English/5010/financial-presentations.html
Today's conference call
A conference call on LifeWatch's half-year results will be held
today at 14.00 CET.
Dial-in numbers for the conference call:CH: +41 22 580 59 70GER:
+49 69 2222 29 043UK: +44 203 00 92 452US: +1 855 402 77
66Participant Pin Code: 60170589#
The live audio webcast and presentation slides will be available
under following link:
http://lifewatch200815-live.audio-webcast.com/
About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss
Exchange (LIFE), Switzerland, is a leading healthcare technology
and solution company, specializing in advanced digital health
systems and wireless remote diagnostic patient monitoring services.
LifeWatch's services provide physicians with critical information
to determine appropriate treatment and thereby improve patient
outcomes. LifeWatch AG has operative subsidiaries in the United
States, in Switzerland and in Israel, and is the parent company of
LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch
Services, Inc. is a leading U.S.-based provider of cardiac
monitoring services and home sleep testing of Obstructive Sleep
Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a
leading developer and manufacturer of telemedicine products. For
additional information, please visit www.lifewatch.com.
Sign up for customized e-mail alerts and documentation
requests at http://www.irlifewatch.com/alert-service.aspx
This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results
of operations and financial position, the business strategy, and
plans and objectives for future operations, are forward-looking
statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar
expressions are intended to identify forward-looking statements.
LifeWatch AG has based these forward-looking statements largely on
current expectations and projections about future events and
financial trends that it believes may affect the financial
condition, results of operations, business strategy, short-term and
long-term business operations and objectives, and financial needs.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions. In light of these risks,
uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could
differ materially and adversely from those anticipated or implied
in the forward-looking statements. All forward-looking statements
are based only on data available to LifeWatch AG at the time of the
issue of this press release. LifeWatch AG does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF
LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED
STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED
STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS
SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN
THE UNITED STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER
OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF
THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF
SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF
A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS
SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION
ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.
Language: English Company: LifeWatch AG Baarerstrasse
139 6300 Zug Switzerland Phone: +41 41 728 67 78 Internet:
www.lifewatch.com
ISIN: CH0012815459 Valor: 811189 Listed: Regulated Unofficial
Market in Berlin, Stuttgart; Open Market in Frankfurt ; SIX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150819006321/en/
LifeWatch AG c/o Dynamics GroupPhilippe Blangey / Doris
RudischhauserPhone: +41 43 268 32 35 / +41 79 410 81
88investor-relations@lifewatch.com
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024